This Federal Circuit opinion concerns an appeal from Agilent Technologies, Inc. against Synthego Corp., concerning the patentability of gene-editing technology related to CRISPR-Cas systems. Agilent appealed decisions by the Patent Trial and Appeal Board, which found all claims of Agilent's U.S. Patent Nos. 10,337,001 and 10,900,034 unpatentable due to anticipation or obviousness based on prior art. The core of the dispute revolves around whether earlier works, particularly "Pioneer Hi-Bred," "Threlfall," and "Deleavey," expressly disclosed or enabled the chemically modified guide RNAs (gRNAs) and their functionality as claimed by Agilent. The court ultimately affirmed the Board's findings, concluding that substantial evidence supported the prior art's anticipatory disclosures and enablement, as well as the obviousness of certain claims.

This podcast is for entertainment purposes only and does not create an attorney-client relationship. The AI-generated hosts are not attorneys and are not providing legal advice. The choice of a lawyer is an important decision and should not be based solely upon advertisements.